HSBC’s senior research analyst Rajesh Kumar believes Novo Nordisk (NYSE: NVO) “might have an edge” over rival Eli Lilly (NYSE: LLY) heading into 2026. His remarks arrive shortly after the Danish pharmaceutical giant received FDA approval for its oral weight-loss pill – an announcement that triggered a sharp rally in NVO shares on Tuesday. […]